DNA-testing company 23AndMe and its founder, Anne Wojcicki, aimed to revolutionize healthcare, bringing genetic tests to homes with just a tube of spit. But challenges with its business model and continued data privacy concerns for consumers have brought the company once valued at $6 billion to a valuation of nearly $0, with Nasdaq threatening to delist it.

WSJ explains what went wrong with Wojcicki’s biotech business.

0:00 Home DNA testing
0:49 The rise of 23andMe
2:18 The turning point
4:03 23andMe’s fall
5:23 What’s next?

What Went Wrong explores the challenging conditions and decisions that led to a company’s downturn.

#23andMe #DNA #WSJ